|
|
 |
|
Viewing report
|
|
|
|
Malignant Mesothelioma Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, July 2011, Pages: 74
Malignant Mesothelioma Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Malignant Mesothelioma Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global malignant mesothelioma therapeutics market. The report identifies the key trends shaping and driving the global malignant mesothelioma therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global malignant mesothelioma therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global (the US, the UK, France, Germany, Italy, Spain, Japan) malignant mesothelioma therapeutics market was valued at $165m in 2010 and is forecast to grow at a compound annual growth rate (CAGR) of 4.1% to reach $218m by 2017. The current malignant mesothelioma therapeutics market is dominated by the chemotherapeutic regimen, Alimta (pemetrexed), which is a folate antimetabolite in combination with cisplatin. The expected launch of NGR-hTNF (combination of a tumour homing peptide (NGR) with the human tumour necrosis factor (hTNF), Onconase(ranpirnase) and Zolinza (vorinostat) for the second-line treatment in 2014 will drive the market. However, the patent expiry of Alimta in the forecast period will off-set the growth rate.
Scope
The report provides information on the key drivers and challenges of the malignant mesothelioma therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) malignant mesothelioma therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as Tyrosine kinases inhibitor, VEGF inhibitor, Immunomodulators.
- Analysis of the current and future competition in the seven key countries of the malignant mesothelioma therapeutics market. Key market players covered are MolMed S.p.A, Merck and Co., Inc, Tamir Biotechnology Inc., Oxford Biomedica Plc, Canbas Co. Ltd, Bionomics Ltd, and Eisai Co.Ltd.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the malignant mesothelioma therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements malignant mesothelioma therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global malignant mesothelioma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global malignant mesothelioma therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global malignant mesothelioma therapeutics market landscape? – Identify, understand and capitalize.
|
|
|
|
